Abstract. Long noncoding RNAs (lncRNAs) have emerged as key regulatory molecules at almost every level of gene expression regulation. The altered expression of lncRNAs is a characteristic of numerous types of cancer, and lncRNAs have been demonstrated to promote the development, invasion and metastasis of tumors through various mechanisms. However, the role of lncRNAs in papillary thyroid carcinoma (PTC) remain unclear. In the present study, differentially expressed lncRNAs and mRNAs were detected by human lncRNA microarray in three pairs of PTC and adjacent noncancerous samples. The microarray results revealed that 675 lncRNAs and 751 mRNAs were abnormally expressed in the three PTC samples compared with adjacent noncancerous samples (fold change ≥2.0; P<0.05). To validate the microarray results, 8 differentially expressed lncRNAs were randomly selected for quantitative polymerase chain reaction (qPCR). The results of qPCR were consistent with the microarray data; the 8 lncRNAs had an aberrant expression in the PTC samples compared with the adjacent noncancerous samples. Gene ontology and pathway analysis indicated that there were 7 downregulated pathways and 29 upregulated pathways in PTC. LncRNA classification and subgroup analysis revealed 7 pairs of enhancer-like lncRNA-mRNA, 9 pairs of antisense lncRNA-mRNA and 45 pairs of lncRNA-mRNA were differentially expressed between PTC and their paired noncancerous samples. In conclusion, the present study identified a series of novel PTC-associated lncRNAs. Further study with these lncRNAs is instrumental for the identification of novel target molecules that could lead to improved diagnosis and treatment for
Introduction
In the majority of regions of the world, thyroid cancer incidence has increased over the last few decades (1) . Papillary thyroid carcinoma (PTC) is the most common thyroid cancer, accounting for 85-95% of thyroid cancer (1) (2) (3) (4) . Potential risk factors for PTC include a family history of thyroid cancer, radiation exposure and abnormal iodine intake (4-7). In recent years, studies have demonstrated that genomic instability, alterations in epigenetic events and subsequent inappropriate gene expression are key in the regulation of PTC (8, 9) . However, the mechanisms underlying PTC pathogenesis have not been elucidated.
Recent studies have revealed a complex involvement of epigenetic mechanisms in the regulation of gene expression, including the diverse activities of noncoding RNAs (ncRNAs) (10, 11) . The roles of microRNAs have been relatively well studied in PTC, but other studies have revealed that alterations in PTC-associated long noncoding RNAs (lncRNAs) may lead to an altered regulation of key genes (12, 13) . lncRNAs are transcript RNA molecules, >200 nucleotides in length, that do not encode proteins. lncRNAs are among the least well-understood of ncRNA species; however, they cannot be dismissed as transcriptional 'noise'. Thousands of lncRNAs have recently been described in mammals (14) . Studies have revealed that an aberrant expression of lncRNAs results in abnormalities in gene expression and tumorigenesis. In addition, an altered expression of lncRNAs is a characteristic of numerous types of cancers, which have been revealed to promote the development, invasion and metastasis of tumors through various mechanisms (15) (16) (17) . However, study concerning lncRNA involvement in PTC is in its infancy, and the identification of additional PTC-associated lncRNAs and their mechanisms of action require additional investigation.
The present study profiled the expression of lncRNAs and mRNAs in three paired PTC and adjacent noncancerous samples via microarray analysis, and identified a series of novel PTC-associated lncRNAs. In addition, the present study demonstrated that genes associated to these lncRNAs were associated with risk factors for tumorigenesis. The present results suggest that lncRNA expression patterns may provide novel molecular biomarkers for the diagnosis of and methods for treating PTC. To investigate the association between lncRNAs and their coding genes, lncRNAs with enhancer-like function were identified using the Gencode annotation of human genes (18) . The selection of lncRNAs with enhancer-like function involved the exclusion of transcripts mapped to the exons and introns of annotated protein coding genes. These enhancer lncRNAs and the corresponding mRNAs (<300 kb) were integrated in order to study the potential function of the lncRNAs.
The function of antisense lncRNAs were identified based on the study by Faghihi and Wahlestedt (19) . The present study integrated the differentially expressed antisense lncRNAs and corresponding sense mRNAs in order to deduce the function of the lncRNAs.
LincRNAs is a current hotspot of research. The function of lincRNAs were identified by the present study based on the (20) . In order to deduce the function of these differentially expressed lincRNAs, the lincRNAs and corresponding nearby mRNAs underwent conjoint analysis.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
RT-qPCR was performed to confirm the expression of lncRNAs identified by microarray analysis. In total, 8 lncRNAs (upregulated: ENST00000503723, ENST00000423539, uc003tab.3, NR_073085; downregulated: ENST00000515275, ENST00000570022, uc003qef.1, ENST00000427243) were selected to undergo qPCR analysis in 33 paired PTC and adjacent noncancerous samples. Total RNA was extracted from 33 frozen tumor specimens using TRIzol Reagent and subsequently reverse transcribed into cDNA using PrimeScript RT reagent kit (Invitrogen™), according to the manufacturer's protocol. DNase (1 µl; 1 U/µl) was purchased from Invitrogen™. qPCR was performed using SYBR Green Real-Time PCR Master Mix (Invitrogen™), according to the manufacturer's protocol, on a MasterCycler RealPlex (Eppendorf, Hamburg, Germany). The following cycling conditions were used: 95˚C for 2 min; and 95˚C for 15 sec, 57˚C for 15 sec, 72˚C for 1 min for a total 40 cycles. The primers used for the 8 lncRNAs are listed in Table II and were synthesized by Invitrogen™. Glyceraldehyde 3-phosphate dehydrogenase was used as a reference gene with the following primers: Forward, 5'-GAA AGC CTG CCG GTG ACT AA-3' and reverse, 5'-AGG AAA AGC ATC ACC CGG AG-3'. For quantitative results, the expression of each lncRNA was represented as a fold change (FC) using 2 -ΔΔCq (21) . The experiment was repeated three times.
Statistical analysis. Statistical analysis was performed using Student's t-test for the comparison of two groups in the microarray. FC and the t-test were used to analyze the statistical significance of the microarray results. The false discovery rate was calculated to correct the P-value. The threshold value used to designate differentially expressed lncRNAs and mRNAs was a fold change of ≥2.0 or ≤0.5, P<0.05. P<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed with SPSS version 13 software (SPSS, Inc., Chicago, IL, USA).
Results

Expression profile of lncRNAs and mRNAs in PTC.
Using microarray analysis, the present study examined the lncRNA and mRNA expression profiles in human paired PTC and adjacent noncancerous tissue samples (Exp vs. Ctrl). FC (T/N) and P-value were calculated from the normalized expression. Microarray analysis revealed that 675 lncRNAs and 751 mRNAs were significantly differentially expressed in PTC samples compared with their adjacent noncancerous tissue samples (FC ≥2.0; P<0.05). Among the lncRNAs, 312 were upregulated and 363 were downregulated. Among the mRNAs, 499 were upregulated and 252 were downregulated. Hierarchical clustering analysis was used to arrange the differentially expressed lncRNAs into groups based on their expression levels. A dendrogram revealed the lncRNA expression patterns among samples (FC ≥4.0; P<0.01; Fig. 1 ). ENST00000503723 (FC=24.501809) was the most upregulated lncRNA, and ENST00000515275 (FC=14.349726) was the most downregulated lncRNA.
Gene ontology analysis. Corresponding to the downregulated mRNAs, the total number of differentially expressed genes consisted of 159 genes involved in biological processes, 187 genes involved in cellular components and 170 genes involved in molecular functions. The highest enriched GOs targeted by downregulated transcripts were negative regulation of transporter activity (biological process), myofibril (cellular component) and oxygen transporter activity (molecular function).
Corresponding to the upregulated mRNAs, the total number of differentially expressed genes consisted of 362 genes involved in biological processes, 376 genes involved in cellular components and 359 genes involved in molecular functions. The highest enriched GOs targeted by the upregulated transcripts were response to stimulus (biological process), plasma membrane (cellular component) and protein binding (molecular function).
Pathway analysis. Pathway analysis indicated that there were 7 downregulated pathways ( Fig. 2A) , and the most enriched network was 'Fc epsilon RI signaling pathway-Homo sapiens (human)', which was composed of 4 targeted genes. Furthermore, the analysis revealed that of the 29 upregulated pathways (Fig. 2B) identified, the most enriched network was 'p53 signaling pathway-Homo sapiens (human)', which was composed of 13 targeted genes.
Classification and subgroup analysis. LncRNA classification and subgroup analysis indicated that 7 pairs of enhancer-like lncRNA-mRNA (Table III) , 9 pairs of antisense lncRNA-mRNA (Table IV) and 45 pairs of lincRNA-mRNA (Table V) were differentially expressed between PTC and their paired adjacent noncancerous samples.
RT-qPCR results.
To verify the microarray data, 8 differentially expressed lncRNAs, including 4 upregulated (ENST00000503723, ENST00000423539, uc003tab.3 and NR_073085) and 4 downregulated (ENST00000515275, ENST00000570022, uc003qef.1 and ENST00000427243) lncRNAs, were randomly selected for RT-qPCR in 33 pairs of PTC and adjacent noncancerous tissues. The results were consistent with the microarray data (Fig. 3) .
Discussion
PTC is a common malignant tumor of the endocrine system that occurs more often in women than men (22) . The incidence of PTC has increased globally for several decades. The tumorigenesis of PTC is a complex biological process characterized by various molecular abnormalities. Over the past few decades, the molecular mechanism of PTC has been extensively investigated; however, the exact pathogenesis of this disease remains unclear. Increasing evidence suggests that lncRNAs may be significant in regulating gene expression. LncRNA have gained considerable attention and have become the frontiers of ncRNA research. Although lncRNAs were initially indicated to be transcriptional noise, studies suggest that they may be key in cellular development and human diseases (23, 24) , including lnc-IL7R in the inflammatory response (25) , and HOTAIR and Gas5 in breast tumors and metastases (16, 26, 27) . Aberrant expression of lncRNAs were also identified in the present study in PTC using microarray data, including HOTAIR, which was downregulated; however, this was not statistical significant. Of all the functions of lncRNAs, the most important is their involvement in tumorigenesis. However, the role of lncRNAs in tumor pathogenesis and development is less well characterized.
The present study investigated the lncRNA expression profiles of PTC using microarray analysis and revealed that lncRNA expression levels were altered compared to adjacent noncancerous tissues. From the microarray expression 
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profiles, 312 upregulated lncRNAs and 363 downregulated lncRNAs were significantly differentially expressed in all PTC samples. The most upregulated lncRNA was ENST0 0 0 0 0503723, and the most down regulated lncRNA was ENST00000515275. This result suggests that ENST00000503723 and ENST00000515275 may contribute to the development of PTC; however, additional study concerning the biological function of these two lncRNAs requires confirmation. To validate the microarray profiling expression data, the expression of 8 randomly selected lncRNAs were examined in PTC and adjacent noncancerous samples by RT-qPCR. The RT-qPCR results confirmed the data from the microarray. The present results demonstrated an altered expression profile of lncRNAs in PTC. Additional analysis by the present study highlighted that numerous genes associated with these lncRNAs were associated with various types of cancer, including ENST00000427243, uc003qef.1 and NR_073085. 
ENST00000427243 was significantly downregulated in PTC and was identified to be associated with breast cancer anti-estrogen resistance protein 3 (BCAR3) gene. BCAR3 overexpression results in enhanced cancer cell migration and colocalization (28) . By contrast, BCAR3 depletion inhibits cancer cell migration and invasion (29) . In addition, BCAR3 functions as a positive regulator in invasive breast cancer cells (30) and acts as a putative suppressor of breast cancer progression (31) . Therefore, there may be an association between ENST00000427243 lncRNA and BCAR3 in the development of PTC, and BCAR3 may aid in the understanding of PTC and lncRNAs at the transcriptional level. uc003qef.1 was also identified to be significantly downregulated in the present results. Its associated gene was eyes absent homolog 4 (EYA4). Decreased EYA4 expression is not only associated with poor survival in sporadic lung cancer, but also EYA4 single-nucleotide polymorphisms have been associated with an increased familial cancer risk (32) . The present study concludes that uc003qef.1 may play an important role with EYA4 in the familial cancer risk of PTC.
NR_073085 was identified to be significantly upregulated in PTC samples by the present study. NR_073085 was associated with cysteine-rich protein 2 (CRIP2), which was identified as an important candidate gene capable of functionally suppressing tumor formation (33) . CRIP2 is significantly downregulated in tumors, and an overexpression of CRIP2 may induce cancer cell apoptosis (33) . Furthermore, CRIP2 acts as a transcriptional repressor of the nuclear factor-κB-mediated proangiogenic cytokine expression, and thereby functionally inhibits tumor formation and angiogenesis (34) . NR_073085 may be significant in the regulation of CRIP2 during tumor progression. The association between NR_073085 and PTC requires additional experimental verification.
The microarray-based profiling performed by the present study identified 751 mRNAs with a differential expression in PTC. GO analysis and pathway analysis indicated that there were 7 downregulated and 29 upregulated pathways in PTC compared with adjacent non-tumorous tissues. Among the upregulated pathways, the p53 signaling pathway was the most enriched network. Lan et al (35) also demonstrated that the p53 signaling pathway was differentially expressed in PTC in a mRNA expression profile study. It is known that p53 plays an important tumor suppressive role during thyroid carcinoma progression (36) . Signaling pathways that use lncRNAs to regulate the growth and metastasis of tumors require additional study to be identified. Furthermore, lncRNA classification and subgroup analysis performed by the present study indicated 61 pairs of lncRNA-mRNA were differentially expressed in PTC. Certain nearby proteins of these lncRNAs were associated with inflammation. It is commonly accepted that cancer is associated with inflammation, and an intense immune infiltrate is often observed with PTC, which may be critical in the regulation of carcinogenesis and carcinoma progression (37) . The present study identified ENST00000423539 as a significantly upregulated enhancer lncRNA in PTC, and the nearby protein was E3 ubiquitin-protein ligase pellino homolog 1 (Peli1). Peli1 regulates Toll-like receptor pathway signaling by promoting the degradation of tumor necrosis factor receptor-associated factor 3, which is a potent inhibitor of mitogen-activated protein kinase activation and gene induction (38) . In addition, Peli1 is a target of microRNA-21 (39), which is significantly downregulated in PTC tissues (40) . ENST00000423539 may exert its functions through interactions with coding transcripts in PTC. The inflammatory pathways of cancer-associated inflammation is critical for the identification of novel target molecules that may lead to improved diagnosis and treatment.
In conclusion, the present study demonstrated the existence of a significantly altered lncRNA and mRNA expression profile in PTC. Dysregulation of these lncRNAs may be important in the development, invasion and metastasis of tumors. Additional study is required to determine whether these alterations are indirectly due to genotype, familial cancer risk, inflammatory states or a combination of these cancer risk factors. Further molecular mechanism studies may aid in the elucidation of the exact roles of these lncRNAs in PTC.
